Alnylam Pharmaceuticals, Inc (ALNY)

Etorro trading 970x250
Alnylam Pharmaceuticals, Inc (ALNY) Logo

About Alnylam Pharmaceuticals, Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142

Alnylam Pharmaceuticals, Inc News and around…

Latest news about Alnylam Pharmaceuticals, Inc (ALNY) common stock and company :

11 Best Genomic Stocks to Buy Now
19 Oct, 2021 Yahoo! Finance

In this article, we will take a look at the 11 best genomic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Genomic Stocks to Buy Now. Genomics is a branch of biology that studies the structure, function, evolution, mapping, and editing of genomes, […]

Notable Monday Option Activity: ALNY, NBIX, DDD
18 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Alnylam Pharmaceuticals Inc (ALNY), where a total of 2,632 contracts have traded so far, representing approximately 263,200 underlying shares. That amounts to about 50.2% of ALNY's average daily trading volume over the past month of 524,430 shares..

Alnylam Pharmaceuticals, Inc. (ALNY) Fell Out Of Favor With Hedge Funds?
18 Oct, 2021 Yahoo! Finance

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI® for the Treatment of Acute Hepatic Porphyria (AHP) in Adults
18 Oct, 2021 Yahoo! Finance

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is pleased to announce that GIVLAARI® (givosiran) has now received a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH). GIVLAARI® is approved by Health Canada for subcutaneous use for the treatment of acute hepatic porphyria (AHP) in adults.1

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
18 Oct, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

3 Top Breakout Stocks to Buy Right Now
15 Oct, 2021 FinancialContent

They're near record highs and their momentum could continue.

Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
14 Oct, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday, October 28, 2021, before the U.S. financial markets open.

3 Growth Stocks Near 52-Week Highs to Buy Anyway
14 Oct, 2021 FinancialContent

These top performers have what it takes to keep providing outsized gains for patient investors.

Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
13 Oct, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity. Through this program, Alnylam will collaborate with social entrepreneurs, employees, and business partners to create innovative health solutions to tackle obstacles to accessing health care such as poverty, racial discrimination, and other social determinants of health.

Alnylam Announces Launch of "Alnylam Challengers," a Signature Community Impact Program to Improve Health Access to Underserved Communities
13 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., October 13, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity. Through this program, Alnylam will collaborate with social entrepreneurs, employees, and business partners to create innovative health soluti

Where Alnylam Pharmaceuticals Stands With Analysts
12 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: ...

Here's Why Inhibrx Stock Is on the Move Today
12 Oct, 2021 FinancialContent

The first clinical trial results for a candidate for the treatment of alpha-1 antitrypsin deficiency look highly encouraging.

Notable Friday Option Activity: ALNY, WFC, COP
08 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Alnylam Pharmaceuticals Inc (ALNY), where a total of 2,340 contracts have traded so far, representing approximately 234,000 underlying shares. That amounts to about 40.4% of ALNY's average daily trading volume over the past month of 578,690 shares..

10 Health Care Stocks With Unusual Options Alerts In Today's Session
08 Oct, 2021 FinancialContent

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances ...

Analyst Ratings For Alnylam Pharmaceuticals
04 Oct, 2021 FinancialContent

Over the past 3 months, 7 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are ...

Stocks Showing Improving Market Leadership: Alnylam Pharmaceuticals Earns 86 RS Rating
01 Oct, 2021 FinancialContent

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 86.

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
29 Sep, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership. The research was presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 26 – 29, 2021. Among the presentations from Alnylam scientists, new pre-clinical data were presented identifying a hexadecyl (C16) moiety as a lipophilic ligand by which conjugation to siRNAs enables the potential for safe, robust, and durable target knockdown in the central nervous system following intrathecal administration. In addition, pre-clinical platform data were presented highlighting the Company’s extended duration platform, called IKARIA™, which has the potential to enable highly potent (i.e., >90 percent) target mRNA silencing with an annual dosing regimen.

Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
28 Sep, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET.

Notable Tuesday Option Activity: ALNY, SUI, EA
28 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Alnylam Pharmaceuticals Inc (ALNY), where a total of 2,703 contracts have traded so far, representing approximately 270,300 underlying shares. That amounts to about 49.4% of ALNY's average daily trading volume over the past month of 547,695 shares..

ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR)
28 Sep, 2021 Yahoo! Finance

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is pleased to announce that ONPATTRO® (patisiran) is now reimbursed almost everywhere in Canada for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy. This comes following a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et services sociaux (INESSS).

Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
14 Sep, 2021 Yahoo! Finance

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Noteworthy Monday Option Activity: CEVA, RGR, ALNY
13 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ceva Inc (CEVA), where a total volume of 3,772 contracts has been traded thus far today, a contract volume which is representative of approximately 377,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 309.5% of CEVA's average daily trading volume over the past month, of 121,885 shares..

Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
13 Sep, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy.

Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
07 Sep, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. Data presented at the 3rd European ATTR Amyloidosis Meeting further supports and builds on the previously reported primary and secondary endpoint results of the HELIOS-A study in hereditary ATTR amyloidosis patients with polyneuropathy, with improvements observed across important areas of patient health and function, including neuropathy impairment, Quality of Life (QoL), ability to perform daily activities and social engagement, nutritional status, and cardiac stress.

Alnylam (ALNY) Up 7.4% Since Last Earnings Report: Can It Continue?
02 Sep, 2021 Yahoo! Finance

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam to Webcast Presentations at Upcoming September Investor Conferences
01 Sep, 2021 FinancialContent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 36% Undervaluation?
19 Aug, 2021 Yahoo! Finance

Does the August share price for Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) reflect what it's really worth? Today, we...

This Robot-Run Large Cap ETF Has Less Apple, Microsoft, Amazon, Facebook Compared To SPY And Is Bullish On These Manufacturing Stocks Instead
18 Aug, 2021 FinancialContent

The Qraft AI-Enhanced US Large Cap ETF (NYSE: QRFT) has revealed that it has less holdings in “big tech” companies such as ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Notable Wednesday Option Activity: ALNY, SPOT, EXC
11 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alnylam Pharmaceuticals Inc (ALNY), where a total volume of 4,511 contracts has been traded thus far today, a contract volume which is representative of approximately 451,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 66.5% of ALNY's average daily trading volume over the past month, of 678,475 shares..

Alnylam Pharmaceuticals, Inc (ALNY) is a NASDAQ Common Stock listed in , ,

970x250